The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 11)
Research Grant, 2016
GBA Meta-analysis Initiative: Charting a Path to Success for Clinical Trials in Patients with GBA-PD
Promising Outcomes of Original Grant:
We ascertained the associations between GBA mutations and cognitive and motor outcomes in seven large cohorts representing 2,304 patients with PD (including 221 carrying a GBA mutation) and 20,868 longitudinal study visits conducted in England, the Netherlands, France, Canada and the United States. This study found that GBA mutations hasten the longitudinal pro...
Rapid Response Innovation Awards, 2013
Alpha-synuclein Picobody: A Novel Blood-Brain Barrier Permeable Diagnostic Ligand for Parkinson's Disease
The presence of the blood-brain barrier (BBB) has been an insurmountable impediment to successful drug delivery to the central nervous system. To circumvent the BBB challenge, ICBI has developed Picotechnology to deliver a novel class of antibodies termed 'picobodies' of ~50 kDa to the CNS. Since compelling evidence have identified a-synuclein (a-syn) as a key fac...
Access to Data and Biospecimens, 2013
Alpha-Galactosidase A and Glycosphingolipid Metabolites as Putative Biomarkers for Parkinson's Disease
Alpha Galactosidase A (alpha-Gal A) is an enzyme that is ordinarily responsible for lipid recycling in cells. Researchers have shown how pre-clinical models that lack alpha-Gal A have increased levels of alpha-synuclein, a protein associated with Parkinson's disease. This project will determine if alpha-Gal A is present at lower levels or has less function in Parki...
Neuropathological studies have been vital in Parkinson’s disease (PD) research. The gold-standard diagnosis of PD is confirmed at autopsy. In addition, information on key proteins and cellular processes involved in PD is obtained from autopsy neuropathological samples. Here, we form an international collaborative group committed to uniform collection, storage and processing o...
Rapid Response Innovation Awards, 2011
Although the association between Parkinson's disease (PD) and melanoma has been well established, biological explanations are still lacking. PD-causing gene alpha-synuclein is highly expressed in some melanoma tissue/cells and its immunoreactivity in cutaneous peripheral nerves is increased in PD patients. We hypothesize that alpha-synuclein may be one of the points for the l...
Researchers: Tianhong Pan, MD, PhD